Federated Hermes Inc. cut its holdings in Agilent Technologies, Inc. (NYSE:A - Free Report) by 50.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,008 shares of the medical research company's stock after selling 33,011 shares during the period. Federated Hermes Inc.'s holdings in Agilent Technologies were worth $4,434,000 as of its most recent SEC filing.
A number of other large investors have also recently added to or reduced their stakes in the business. CKW Financial Group lifted its position in shares of Agilent Technologies by 114.9% in the fourth quarter. CKW Financial Group now owns 187 shares of the medical research company's stock valued at $25,000 after acquiring an additional 100 shares in the last quarter. Global X Japan Co. Ltd. raised its stake in Agilent Technologies by 161.1% in the 4th quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company's stock valued at $25,000 after purchasing an additional 116 shares during the last quarter. Lee Danner & Bass Inc. purchased a new position in Agilent Technologies in the 4th quarter valued at about $29,000. Hanson & Doremus Investment Management boosted its stake in shares of Agilent Technologies by 66.5% during the 4th quarter. Hanson & Doremus Investment Management now owns 263 shares of the medical research company's stock worth $35,000 after purchasing an additional 105 shares during the last quarter. Finally, OFI Invest Asset Management purchased a new stake in shares of Agilent Technologies during the fourth quarter worth about $37,000.
Agilent Technologies Stock Down 2.0 %
Shares of NYSE:A traded down $2.13 during midday trading on Tuesday, hitting $103.06. 1,326,712 shares of the company's stock traded hands, compared to its average volume of 1,856,678. The firm's fifty day moving average price is $122.90 and its two-hundred day moving average price is $133.54. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.66 and a current ratio of 2.20. Agilent Technologies, Inc. has a twelve month low of $96.43 and a twelve month high of $155.35. The company has a market cap of $29.38 billion, a PE ratio of 23.69, a P/E/G ratio of 2.89 and a beta of 1.19.
Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, topping analysts' consensus estimates of $1.27 by $0.04. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. The company had revenue of $1.68 billion for the quarter, compared to analysts' expectations of $1.67 billion. On average, equities research analysts anticipate that Agilent Technologies, Inc. will post 5.55 EPS for the current fiscal year.
Agilent Technologies Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Stockholders of record on Tuesday, April 1st will be paid a $0.248 dividend. The ex-dividend date is Tuesday, April 1st. This represents a $0.99 annualized dividend and a dividend yield of 0.96%. Agilent Technologies's dividend payout ratio (DPR) is presently 22.76%.
Analysts Set New Price Targets
A number of analysts recently issued reports on A shares. TD Cowen raised their target price on shares of Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research report on Thursday, April 10th. Barclays decreased their price objective on Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Robert W. Baird reduced their target price on Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating on the stock in a research report on Thursday, February 27th. Citigroup raised their price target on Agilent Technologies to $165.00 and gave the stock a "buy" rating in a research note on Thursday, December 19th. Finally, StockNews.com raised shares of Agilent Technologies from a "hold" rating to a "buy" rating in a research note on Tuesday, December 24th. Seven analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Agilent Technologies presently has a consensus rating of "Moderate Buy" and an average price target of $146.25.
Check Out Our Latest Research Report on A
Insider Buying and Selling
In other Agilent Technologies news, VP Rodney Gonsalves sold 1,908 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $121.98, for a total transaction of $232,737.84. Following the transaction, the vice president now directly owns 21,786 shares in the company, valued at $2,657,456.28. This represents a 8.05 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Padraig Mcdonnell sold 1,911 shares of the business's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the completion of the sale, the chief executive officer now directly owns 39,652 shares of the company's stock, valued at $5,947,800. The trade was a 4.60 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 5,638 shares of company stock valued at $731,229 in the last quarter.
About Agilent Technologies
(
Free Report)
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
See Also
Before you consider Agilent Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.
While Agilent Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
